News & Media

NextRNA Therapeutics Appoints Seasoned Industry Leader Charles Kunsch, Ph.D. to Board of Directors

NextRNA Therapeutics Expands Executive Team with Appointment of Jesse Smith, PhD as Chief Scientific Officer

Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in Oncology

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

NextRNA Therapeutics to Participate in Upcoming 5th Annual RNA-Targeted Drug Discovery Summit

NextRNA Therapeutics to Participate in Upcoming BioPharm America and Chardan’s 6th Annual Genetic Medicines Conference

NextRNA Therapeutics names Dominique Verhelle as CEO and expands leadership team

NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients

The ‘Junk’ Genome May Actually Unlock The Next Cancer Treatment

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Bayer and NextRNA sign $500M+ lncRNA oncology deal

Bayer pens $547M biobucks pact with biotech pushing the boundaries of noncoding RNA FierceBiotech

Bayer partners with NextRNA on lncRNA-targeted small molecules for cancer

Bayer partners with RNA drugmaker to develop new cancer therapies

Bayer signs $547 million pact with NextRNA in oncology push

Boston biotech signs deal with Bayer worth up to $547 million

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with Rory Johnson, PhD

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with Susan Carpenter, PhD

The Long and Short of It: Exploring the Therapeutic Potential of lncRNAs

Q&A with John Mattick, PhD